Treatment for mitochondrial disorders

医学 粒线体疾病 梅德林 临床试验 呼吸链 疾病 心理干预 线粒体呼吸链 内科学 重症监护医学 儿科 物理疗法 线粒体DNA 精神科 线粒体 生物化学 化学 生物 政治学 法学 基因 细胞生物学
作者
Gerald Pfeffer,Kari Majamaa,Douglass M. Turnbull,David R. Thorburn,Patrick F. Chinnery
出处
期刊:The Cochrane library [Elsevier]
被引量:229
标识
DOI:10.1002/14651858.cd004426.pub3
摘要

Background Mitochondrial respiratory chain disorders are the most prevalent group of inherited neurometabolic diseases. They present with central and peripheral neurological features usually in association with other organ involvement including the eye, the heart, the liver, and kidneys, diabetes mellitus and sensorineural deafness. Current treatment is largely supportive and the disorders progress relentlessly causing significant morbidity and premature death. Vitamin supplements, pharmacological agents and exercise therapy have been used in isolated cases and small clinical trials, but the efficacy of these interventions is unclear. The first review was carried out in 2003, and identified six clinical trials. This major update was carried out to identify new studies and grade the original studies for potential bias in accordance with revised Cochrane Collaboration guidelines. Objectives To determine whether there is objective evidence to support the use of current treatments for mitochondrial disease. Search methods We searched the Cochrane Neuromuscular Disease Group Specialized Register (4 July 2011), CENTRAL (2011, Issue 2, MEDLINE (1966 to July 2011), and EMBASE (January 1980 to July 2011), and contacted experts in the field. Selection criteria We included randomised controlled trials (including cross‐over studies). Two of the authors independently selected abstracts for further detailed review. Further review was performed independently by all five authors to decide which trials fit the inclusion criteria and graded risk of bias. Participants included males and females of any age with a confirmed diagnosis of mitochondrial disease based upon muscle histochemistry, respiratory chain complex analysis of tissues or cell lines or DNA studies. Interventions included any pharmacological agent, dietary modification, nutritional supplement, exercise therapy or other treatment. The review authors excluded studies at high risk of bias in any category. The primary outcome measures included an change in muscle strength and/or endurance, or neurological clinical features. Secondary outcome measures included quality of life assessments, biochemical markers of disease and negative outcomes. Data collection and analysis Two of the authors (GP and PFC) independently identified studies for further evaluation from all abstracts within the search period. For those studies identified for further review, all five authors then independently assessed which studies met the entry criteria. For the included studies, we extracted details of the number of randomised participants, treatment, study design, study category, allocation concealment and other risk of bias criteria, and participant characteristics. Analysis was based on intention‐to‐treat data. We planned to use meta‐analysis, but this did not prove necessary. Main results The authors reviewed 1335 abstracts, and from these identified 21 potentially eligible abstracts. Upon detailed review, 12 studies fulfilled the entry criteria. Of these, eight were new studies that had been published since the previous version of this review. Two studies which were included in the previous version of this review were excluded because of potential for bias. The comparability of the included studies is extremely low because of differences in the specific diseases studied, differences in the therapeutic agents used, dosage, study design, and outcomes. The methodological quality of included studies was generally high, although risk of bias was unclear in random sequence generation and allocation concealment for most studies. Otherwise, the risk of bias was low for most studies in the other categories. Serious adverse events were uncommon, except for peripheral nerve toxicity in a long‐term trial of dichloroacetate (DCA) in adults. One trial studied high‐dose coenzyme Q10 without clinically meaningful improvement (although there were multiple biochemical, physiologic, and neuroimaging outcomes, in 30 participants). Three trials used creatine monohydrate alone, with one reporting evidence of improved measures of muscle strength and post‐exercise lactate, but the other two reported no benefit (total of 38 participants). One trial studied the effects of a combination of coenzyme Q10, creatine monohydrate, and lipoic acid and reported a statistically significant improvement in biochemical markers and peak ankle dorsiflexion strength, but overall no clinical improvement in 16 participants. Five trials studied the effects of DCA: three trials in children showed a statistically significant improvement in secondary outcome measures of mitochondrial metabolism (venous lactate in three trials, and magnetic resonance spectroscopy (MRS) in one trial; total of 63 participants). One trial of short‐term DCA in adults demonstrated no clinically relevant improvement (improved venous lactate but no change in physiologic, imaging, or questionnaire findings, in eight participants). One longer‐term DCA trial in adults was terminated prematurely due to peripheral nerve toxicity without clinical benefit (assessments included the GATE score, venous lactate and MRS, in 30 participants). One trial using dimethylglycine showed no significant effect (measurements of venous lactate and oxygen consumption (VO2) in five participants). One trial using a whey‐based supplement showed statistically significant improvement in markers of free radical reducing capacity but no clinical benefit (assessments included the Short Form 36 Health Survey (SF‐36) questionnaire and UK Medical Research Council (MRC) muscle strength, in 13 participants). Authors' conclusions Despite identifying eight new trials there is currently no clear evidence supporting the use of any intervention in mitochondrial disorders. Further research is needed to establish the role of a wide range of therapeutic approaches. We suggest further research should identify novel agents to be tested in homogeneous study populations with clinically relevant primary endpoints.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
火星上含芙完成签到 ,获得积分10
1秒前
量子星尘发布了新的文献求助10
3秒前
3秒前
掌门发布了新的文献求助10
3秒前
愉快的花卷完成签到,获得积分10
3秒前
少言完成签到,获得积分10
5秒前
kiko完成签到,获得积分10
6秒前
隐形惜筠完成签到 ,获得积分10
8秒前
黑眼圈完成签到,获得积分10
12秒前
123发布了新的文献求助10
14秒前
15秒前
16秒前
又又妈妈完成签到,获得积分10
16秒前
欢呼的丁真完成签到,获得积分10
17秒前
ty发布了新的文献求助10
17秒前
Faded完成签到 ,获得积分10
18秒前
ding应助Amorfati采纳,获得10
18秒前
好好学习天天向上完成签到,获得积分10
19秒前
所所应助lh采纳,获得10
20秒前
李爱国应助深情丸子采纳,获得10
20秒前
烟花应助阿湫采纳,获得10
20秒前
20秒前
乌梅不乌发布了新的文献求助10
21秒前
21秒前
YY完成签到,获得积分10
22秒前
23秒前
23秒前
Tiam发布了新的文献求助10
23秒前
种花家的狗狗完成签到,获得积分10
23秒前
wisdom完成签到,获得积分10
23秒前
123完成签到,获得积分10
24秒前
温暖芸完成签到,获得积分10
24秒前
25秒前
认真的觅松完成签到 ,获得积分10
26秒前
bkagyin应助12采纳,获得10
26秒前
gougoutu发布了新的文献求助10
26秒前
老菜鸟321发布了新的文献求助10
26秒前
27秒前
完美世界应助温暖芸采纳,获得10
27秒前
贺贺发布了新的文献求助10
28秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048